Over the past thirty five years the Clinical Research industry has progressed from a few small entrepreneurial providers offering a pressure valve to the pharmaceutical industry to a well reputable multi billion industry, increasing by 10-15% annually and employing roughly 100,000 specialists in hundreds of Clinical Research Organisations globally.
There has been a proliferation of companies, amalgamations and acquisitions which has lead to the structure of some very large international companies employing as many as 15,000 employess globally. However, the market place is as different and as open for new projects as it has been for many years; just very larger in size.
sadly, one of the biggest drivers for the growth of this industry has been the ever escalating regulatory requirements rather than an enhancement in real innovation. Yet new approaches in drug development such as personalised medicines and the advancement of biological medicines will undoubtedly evolve the face of this industry. It is likely to continue to thrive but more in terms of size and diversity.
Entering uncharted territories is the building blocks of all research and as such requires a constantly broadening range of specialists who can add to the new challenges within clinical research.
Partnerships and close alliances have been the buzzword of the industry over many years and indeed it would seem like the logical evolution. However the CRO market has not really adopted this concept.The processes by which clinical trial services are purchased have become smarter and more structured. The demand for standardised processes dealing with large amounts of tests and data in some areas of full drug development have created a massive requiremenst and the subsequent formation of large and process driven CROs frequently supplying the major pharmaceutical companies. However, large processing units are not the most suitable environments for real innovation and it is not surprising that big pharmaceutical organisations constantly look for new alliances in the biotechnology and Clinical Research industry.
Innovation is the product of brilliance usually delivered by an individual. However, large development programmes are reliant on large infrastructures. These are very different needs that the industry has and it is unlikely that they will ever be efficiently met by any one CRO company.
However large the portfolio of a CRO may be, the forte of any large organisation is the ability to process large amounts of goods or clinical data management in a uniform way. The advantage of smaller companies is their ability to adapt to new challenges quickly and deliver true innovation. It follows that the diversity we currently see in the CRO market place is likely to continue providing the opportunities for new entrants to the market|However big the Clinical Research Industry is, the strong point of any formidable company is to have consistency with processing large amounts of products, services or data .
the current political moves towards motivating more patients to put themselves forward for trials, does require reassurances to the public with regard to the safety of those Clinical trials London. The number of regulations is likely to increase which will in turn create an increase in bureaucracy. This again will create a demand for larger organisations to process large amounts of data creating very large databases. Yet more regulations do not necessarily make research safer as the recent unprecedented tragedy at Northwick Park Hospital in London has shown. In this instance all relevant regulations were followed yet the information available was not evaluated in the appropriate way and as a consequence a far too high dose was given to a group of six previously healthy volunteers. The challenge in controlling such complex issues is to find and involve a highly specialised expert in a particular field and to ensure that all available data is evaluated appropriately in the approval process. This represents a challenge, and in this instance, again, size will not be the answer.
Innovation and research require a large arsenal of research tools and services as well as an effectively functioning network, facilitating the access to and exchange of information, both on available services and expertise. It is the creation of these knowledge based networks which will create the most exciting opportunities for the future of a diverse and thriving Clinical Research Organisation market.
Related posts:
- Data Entry Jobs From Home If you search for work at home projects online, you...
- The Development of Data Projectors The LCDs utilised in projection systems are generally small reflective...
- Totara Learning Management System Totara is a customised version of Moodle, the planet’s most...
- Resveratrol Supplements Free Trial – 3 Reasons to Try It Not too sure if you should buy Resveratrol Supplements? Below...
- My Natural Bowel Cleanse Free Trial? Astounding Conclusions … They say a leopard never changes its spots and it...